SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Abildgaard Niels) "

Sökning: WFRF:(Abildgaard Niels)

  • Resultat 11-14 av 14
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Abildgaard, Niels, et al. (författare)
  • Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma
  • 2023
  • Ingår i: Clinical Epidemiology. - : Dove Medical Press. - 1179-1349. ; 15, s. 987-999
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Linked health-care registries and high coverage in Nordic countries lend themselves well to epidemiologic research. Given its relatively high incidence in Western Europe, complexity in diagnosis, and challenges in registration, multiple myeloma (MM) wasselected to compare registries in Denmark, Finland, and Sweden.Patients and Methods: Data were obtained from four archetypal registries in each country (spanning January 2005–October 2018):National Patient Registry (NPR), Prescribed Drug Registry (PDR), Cancer Registry (CR), and Cause of Death Registry. Patients newlydiagnosed with MM who received MM-specific treatment were included. PDR/NPR treatment records were used to assess incidentNPR cases. The registration quality of MM-specific drugs in the PDR of each country was also evaluated.Results: In Denmark, only 6% of patients in the NPR were not registered in the CR; in Sweden, it was 16.9%. No systematicdifferences were identified that could explain this discrepancy. In Denmark, lenalidomide and bortezomib were registered in the NPRwith high coverage, but less expensive drugs typically given in combination with bortezomib were not covered in any of the registries.In Finland and Sweden, bortezomib records were not identified in the PDR, but some were in the NPR; other drugs had good coveragein the PDR.Conclusions: The registries evaluated in this study can be used to identify the MM population; however, given the gaps in MMregistration in the Finnish and Swedish CRs, Danish registries provide the most comprehensive datasets for research on treatmentpatterns for MM.
  •  
12.
  • Mylin, Anne K., et al. (författare)
  • N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma
  • 2015
  • Ingår i: Biomarkers in Medicine. - : Future Medicine. - 1752-0363 .- 1752-0371. ; 9:7, s. 679-689
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: To examine whether N-terminal proCNP concentrations in serum is associated with bone destruction in patients with multiple myeloma. Materials and methods: N-terminal proCNP and biochemical bone markers were measured in 153 patients. Radiographic bone disease and skeletal-related events were evaluated at specific time-points. Results: N-terminal proCNP concentrations increased with age. High N-terminal proCNP concentrations were associated with high-risk disease and renal impairment. Renal function explained 22% of the variation. N-terminal proCNP concentrations correlated with serum bone ALP and serum PINP, but lacked association with bone resorption markers, radiographic bone disease and skeletal-related events. Conclusion: Serum N-terminal proCNP are associated with bone formation activity in patients with multiple myeloma, but should be interpreted with caution in patients with renal impairment.
  •  
13.
  • Nahi, Hareth, et al. (författare)
  • Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
  • 2016
  • Ingår i: European journal of haematology. - : Wiley. - 1600-0609 .- 0902-4441. ; 96:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Chromosomal aberrations have significant prognostic importance in multiple myeloma (MM). However, proteasome inhibitors (PI) and IMiDs may partly overcome the poor prognostic impact of some of them. In this study, we investigated a population-based consecutive cohort newly diagnosed patients with MM admitted during a defined time period to hospitals in Denmark, Norway, and Sweden. The impact of treatment modality on the prognostic importance of specific chromosomal aberration was investigated, with special reference to gain 1q21. The median follow-up of patients still alive at analysis was 40 months for the high-dose (HDT)-treated ones and 29 months for the whole population. Three hundred forty-seven patients with a known 1q21 status were included in this study. The 347 patients were divided into three groups, that is, 119 patients with the 1q21 gain, 105 patients with other aberrations (OA), that is, del(13q), del(17p), t(4,14), and/or (14;16), and 123 patients with no aberrations (NA). The groups were compared in terms of overall survival (OS), time to progression (TTP), and response. The 3-yr OS for patients with gain 1q21 was 60% compared to patients with OA 74% and NO 82% (gain 1q21 vs. NO P < 0.001; gain 1q21 vs. OA P = 0.095). If treated with PI or IMiDs, the 3-yr OS was 58% for patients with gain 1q21 compared to patients with OA 78% and NO 78%, respectively (P = 0.041, P = 0.140). In HDT patients, the 3-yr OS was 69% for patients with gain 1q21 compared to patients with OA 84% and NO 88%, respectively (P < 0.008, P = 0.600). Thus, neither HDT nor using PI or IMiDs could overcome the poor prognostic impact of gain 1q21, while these drugs and HDT seemed to improve OS in patients with OA, approaching the survival in NO. Further, gain 1q21 appears to be one of the most important poor prognostic chromosomal aberrations in multiple myeloma with current treatments. Trials using new drugs or allogeneic transplantation are warranted.
  •  
14.
  • Waage, Anders, et al. (författare)
  • Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
  • 2010
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 116:9, s. 1405-1412
  • Tidskriftsartikel (refereegranskat)abstract
    • In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-14 av 14
Typ av publikation
tidskriftsartikel (12)
konferensbidrag (2)
Typ av innehåll
refereegranskat (13)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Abildgaard, Niels (14)
Waage, Anders (13)
Hansson, Markus (7)
Turesson, Ingemar (7)
Mellqvist, Ulf-Henri ... (7)
Ahlberg, Lucia (7)
visa fler...
Nahi, Hareth (6)
Carlson, Kristina (5)
Linder, Olle (4)
Westin, Jan (4)
Lenhoff, Stig (3)
Anttila, Pekka (2)
Ørstavik, Sigurd (2)
Bent-Ennakhil, Nawal (2)
Ma, Yuanjun (2)
Freilich, Jonatan (2)
Juliusson, Gunnar (2)
Axelsson, Per (2)
Carlsson, Kristina (2)
Sonneveld, Pieter (2)
Andreasson, Bjorn (1)
Rubin, Katrine Hass (1)
Gavini, François (1)
Lassenius, Mariann (1)
Toppila, Iiro (1)
Nilsson, Björn (1)
Holmberg, Erik, 1951 (1)
Niroula, Abhishek (1)
Ajore, Ram (1)
Pertesi, Maroulio (1)
Cafaro, Caterina (1)
Thodberg, Malte (1)
Went, Molly (1)
Duran-Lozano, Laura (1)
Lopez de Lapuente Po ... (1)
Halldorsson, Gisli H ... (1)
Thorleifsson, Gudmar (1)
Rafnar, Thorunn (1)
Weinhold, Niels (1)
Thorsteinsdottir, Un ... (1)
Stefansson, Kari (1)
Houlston, Richard (1)
Goetze, Jens P (1)
Alici, Evren (1)
Ólason, Páll I. (1)
Zweegman, Sonja (1)
Klausen, Tobias Wire ... (1)
Dai, Hong Yan (1)
Hjorth-Hansen, Henri ... (1)
Lanng Nielsen, Johan (1)
visa färre...
Lärosäte
Lunds universitet (6)
Linköpings universitet (5)
Karolinska Institutet (4)
Uppsala universitet (3)
Göteborgs universitet (2)
Umeå universitet (2)
Språk
Engelska (14)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (13)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy